Pharma/Biotech News
Subscribe to Pharma/Biotech News
View Sample

FREE Email Newsletter

Daily news and top headlines for drug research professionals

Silver Creek Awarded NIH Grant for Smart Growth Factor Technology

May 6, 2015 9:46 am | News | Comments

Silver Creek Pharmaceuticals, Inc. announced today the award of a Small Business Innovation Research (SBIR) grant from the National Institute of Health (NIH). Proceeds from the award will be used to advance novel "Smart Growth Factors" toward clinical development. Read more...

Aetna Curtails Coverage of Surgical Tool Tied to Cancer Risk

May 6, 2015 9:35 am | by Associated Press | News | Comments

The health insurer Aetna is ending most coverage of hysterectomies performed with a once-popular device that has drawn warnings from federal regulators over a risk for spreading cancer. Read more..

Codeine-Based Cough Suppressant Will be Another Choice for Next Cold-Flu Season

May 6, 2015 8:50 am | by Seth Augenstein, Digital Reporter | News | Comments

A new, codeine-based cough suppressant produced by a British pharmaceutical company was approved by the U.S. Food and Drug Administration. Read more...


Mylan Launches Sovaldi Tablets in India

May 6, 2015 8:21 am | News | Comments

Mylan has launched Gilead Sciences' Sovaldi tablets in India. Read more...

One Step Closer to an Insulin Vaccine for Type 1 Diabetes

May 5, 2015 3:50 pm | by University of Bristol | News | Comments

An international team of researchers from Bristol, Dresden, Munich, Vienna and Denver have successfully completed the first step in the development of an insulin vaccine to prevent type 1 diabetes. Read more...

Trial of New Skin Cancer Drug Begins as First Patient Receives Treatment

May 5, 2015 3:43 pm | by University of Manchester | News | Comments

A patient has become the first to receive a new resistance-busting experimental skin cancer drug with the launch of a phase 1 clinical trial. Read more...

Meet The New CEO of Bristol Myers-Squibb

May 5, 2015 3:34 pm | by Linda A. Johnson, AP Business Writer | News | Comments

Caforio is a physician - a rarity in the biopharmaceutical industry, where most executives trained in law, marketing and business management. Read more...

Kowa Pharmaceuticals: Pitavastatin Safe Compared with Placebo, Other Statins

May 5, 2015 11:39 am | News | Comments

Kowa Pharmaceuticals America, Inc., announced that the results of a meta-analysis of 15 randomized, controlled clinical trials, to assess the effects of Livalo (pitavastatin) on glycemic parameters and new-onset diabetes (NOD) in non-diabetic individuals were presented as a late-breaking abstract at the 83rd European Atherosclerosis Society (EAS) Congress held in Glasgow, UK. Read more..


Bayer Licenses ISIS FXIRx from Isis Pharmaceuticals

May 5, 2015 11:33 am | News | Comments

Bayer HealthCare (Bayer) has entered into an exclusive license agreement with Isis Pharmaceuticals, Inc. on ISIS-FXIRx, an antisense investigational drug in clinical development for the prevention of thrombosis. Read more...

Hepatitis C Therapy Clears Virus in 93% of Patients in BMS-Funded Trial

May 5, 2015 11:11 am | by Stephanie Guzowski, Editor | Articles | Comments

Bristol-Myers Squibb is trying its hand at its own combination of drugs — daclatasvir, asunaprevir, and beclabuvir. A 12-week dose of the investigational three-drug hepatitis C combination cleared the virus in 93 percent with liver cirrhosis who hadn’t previously been treated, finds a study, published today in The Journal of the American Medical Association (JAMA). Read more...

China to Lift Price Controls on Most Drugs Starting June 1st

May 5, 2015 8:35 am | by The Associated Press | News | Comments

Chinese regulators will lift price controls on most pharmaceutical drugs starting June 1 in hopes that the market-driven pricing system will keep medical costs in check. Read more...

Prostate Cancer Treatment Market Value Will Triple to $8.2B by 2023

May 5, 2015 8:33 am | by Raksha Mudbhary, Ph.D., GlobalData Senior Oncology Analyst | Articles | Comments

The global treatment market value for prostate cancer, excluding hormonal and bone therapies, will expand more than threefold from $2.6 billion in 2013 to an estimated $8.2 billion by 2023. Read more...

Researchers "Un-Can" the HIV Virus

May 5, 2015 8:32 am | by University of Montreal | News | Comments

Researchers have identified a way to use a can opener to force the HIV virus to open up and to expose its vulnerable parts. Read more...


Study Points to Possible Treatment for Lethal Pediatric Cancer

May 5, 2015 8:32 am | by National Institute of Health | News | Comments

NIH-funded preclinical study suggests epigenetic drugs may be used to treat leading cause of pediatric brain cancer death. Read more...

UniQuest, AstraZeneca Collaborate on Drug Discovery

May 5, 2015 8:31 am | by University of Queensland | News | Comments

AstraZeneca and UniQuest have formed an open innovation program to support academic research that holds promise of new therapeutic drugs. Read more...

Gilead's Hepatitis C Drugs Made About $4.45B in Sales in Q1

May 4, 2015 3:06 pm | by Ryan Bushey, Associate Editor | Articles | Comments

This news greatly surpassed analyst expectations.

Multiple Types of Resistance to New Lung Cancer Drug Identified

May 4, 2015 12:09 pm | by Dana-Farber Cancer Institute | News | Comments

After identifying three different types of resistance to a promising investigational lung cancer drug in a phase 1 trial, a team of researchers led by Dana-Farber Cancer Institute scientists say new targeted inhibitors and combinations are urgently needed to stay ahead of tumors' constant and varied molecular shape-shifting. Read more...

New Meds Help Drugmakers Weather Strong Dollar, Other Issues

May 4, 2015 9:04 am | by Linda A. Johnson, AP Business Writer | News | Comments

Revenue from important new medicines for various cancers, hepatitis C and more helped top U.S. drugmakers weather unfavorable currency exchange rates and other challenges. Read more...

Pakistani National Sold Drugs for Incurable Conditions, FDA Charges

May 1, 2015 4:28 pm | by Seth Augenstein, Digital Reporter | News | Comments

A Pakistani national has been indicted on fraud and other charges, according to federal authorities, after he allegedly sold bogus drugs to cure serious diseases — some of which are incurable. Read more...

Biotech Workers Win $58 Million Lottery Drawing, to Split Prize

May 1, 2015 12:06 pm | by Seth Augenstein, Digital Reporter | News | Comments

A group of 16 biotech workers at an office in Manhattan won a $58 million Mega Millions jackpot drawing this week, according to multiple reports. Read more...

Braeburn Expands Pipeline to Include Two Schizophrenia Treatments

May 1, 2015 11:47 am | News | Comments

Braeburn Pharmaceuticals announced today that it has expanded its current therapeutic focus beyond addiction and pain to include schizophrenia and other serious psychiatric disorders. Read more..

Bayer's Contraception Safe, Effective: 5-Year Follow-Up Study

May 1, 2015 11:42 am | News | Comments

Bayer HealthCare announced today that a study published online this week in The Journal of Minimally Invasive Gynecology reinforces findings from previous clinical studies that support the effectiveness and safety of the Essure inserts and procedure for hysteroscopic sterilization, or permanent birth control. Read more...

Medicare Data Show Contrast in Generic, Brand Prescribing

May 1, 2015 11:32 am | by Lauran Neergaard, AP Medical Writer | News | Comments

The most-used medicines in Medicare's prescription drug program are generics, but the program spends the most on brand-name drugs, led by the heartburn treatment Nexium, according to an unprecedented release of government data on Thursday. Read more...

AIT's Cystic Fibrosis Treatment Granted European Orphan Drug Designation

May 1, 2015 9:20 am | News | Comments

Advanced Inhalation Therapies Ltd (AIT), a leading anti-microbial therapeutic company, announced that the European Commission, acting on the recommendation from the Committee for Orphan Medicinal Products of the European Medicines Agency, granted orphan medicinal product designation to AIT-CF, the Company's proprietary high dose formulation of nitric oxide (NO), for the treatment of cystic fibrosis. Read more...

AOP Orphan Launches Lojuxta to the Austrian Market

April 30, 2015 4:45 pm | News | Comments

The Austrian pharmaceutical company AOP Orphan, a European pioneer in the field of rare diseases, is launching Lojuxta into the Austrian market. Lojuxta was authorized by the EMA (European Medical Agency) in July 2013. Read more...

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.